Kromasil 1.8 µm UHPLC columns
Kromasil UHPLC columns with 1.8 ?m spherical silica particles are the latest addition to the Classic Kromasil product line. With the highest efficiency, they will give you the best resolution with minimized turnaround time and laboratory costs.
Kromasil UHPLC columns with 1.8 µm spherical silica particles are the latest addition to the Classic Kromasil product line. With the highest efficiency, they will give you the best resolution with minimized turnaround time and laboratory costs.
Kromasil UHPLC columns are a unique opportunity for laboratories searching for reliability and scalability. With the solid Kromasil brand, you can now use the same quality products as your counterparts within the organization, from pure analysis, screening, product discovery and development to production-scale HPLC purification. Methods developed under UHPLC conditions will be easily transferred and scaled up for small quantity HPLC purification in semi-prep scale or even up to process-scale purification of pharmaceuticals or other industrial applications.
For more details on actual stationary phases and columns availability with 1.8 µm particles, please visit
www.kromasil.com/1.8
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
